Murali Janakiram: Targeting cancer stem cells in multiple myeloma
Murali Janakiram, Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, shared on X:
“Our newest review in an important topic – Targeting cancer stem cells in multiple myeloma in Trends in Cancer.
Stem cells are important in MM, can:
- lead to persistent disease relapse
- source of drug resistance problem
- Stem cells are not well defined in MM
General characteristics of MM stem cells In this we describe the emerging different characteristics of MM stem cells.
How does this impact CART / BisAb therapy? We describe how different constructs can lead to escape or targeting of MM cells.
As always we need to embrace the heterogeneity of these MM stem cells and their different functions and Antibodies which can potentially targets these stem cells. Thanks to Dr. Emine Gulsen who is the lead author in this paper.”
Read further.
Source: Murali Janakiram/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023